Safety and efficacy of baricitinib through 128 weeks in an open-label, longterm extension study in patients with rheumatoid arthritis by Keystone, EC, Genovese, MC, Schlichting, DE, de la Torre, I, Beattie, SD, Rooney, TP, Taylor, PC

Use of magnetic resonance imaging to support dose selection in a phase II trial of baricitinib combined with conventional synthetic disease-modifying antirheumatic drugs in rheumat... by Peterfy, C, Dicarlo, J, Emery, P, Genovese, MC, Keystone, EC, Taylor, PC, Schlichting, DE, Beattie, SD, Luchi, M, Macias, W